报价延迟最少15分钟:2025/07/16 03:02 EDT
常规时段
|
|
|
|
|
||||||||||||
|
|
|
|
|
1.82 
|
|
|
| 价值评估 |
|
盈利(现时/预测)
-1.45/-1.43
|
|
企业价值
208.33M
|
| 资产负债 |
|
每股账面净值
5.34
|
| 现金流量 |
|
现金流量率
--
|
| 损益表 |
|
收益
0
|
|
每股收益
--
|
|
同行比较
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
报价延迟最少15分钟：2025/07/16 03:02 EDT
同行比较之报价最少15分钟延迟
|
业务概览
|
|||
| Nkarta Inc is a clinical-stage biopharmaceutical company pioneering the development of allogeneic, off-the-shelf engineered natural killer (NK) cell therapies. The Company is engaged in leveraging the natural potent power of NK cells to identify and kill abnormal cells and recruit adaptive immune effectors to generate responses that are specific and durable. The company is combining its NK expansion platform technology with proprietary cell engineering technologies to generate an abundant supply of NK cells, engineer enhanced NK cell recognition of therapeutic targets, and improve persistence for sustained activity in the body for the treatment of cancer. |
